HUP0102233A2 - 5-HT-receptorokhoz affinitással rendelkező N-[(benzo-dioxanil)-metil]-N-[(4-piperidil)-metil]-amin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
5-HT-receptorokhoz affinitással rendelkező N-[(benzo-dioxanil)-metil]-N-[(4-piperidil)-metil]-amin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0102233A2 HUP0102233A2 HU0102233A HUP0102233A HUP0102233A2 HU P0102233 A2 HUP0102233 A2 HU P0102233A2 HU 0102233 A HU0102233 A HU 0102233A HU P0102233 A HUP0102233 A HU P0102233A HU P0102233 A2 HUP0102233 A2 HU P0102233A2
- Authority
- HU
- Hungary
- Prior art keywords
- disorders
- compounds
- drug
- benzodioxanylmethyl
- piperidyl
- Prior art date
Links
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 title 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 title 1
- SYMCUSRAXPXCEM-UHFFFAOYSA-N O1C(COC2=C1C=CC=C2)CN(C)N1CCCCC1 Chemical class O1C(COC2=C1C=CC=C2)CN(C)N1CCCCC1 SYMCUSRAXPXCEM-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010010774 Constipation Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000027776 Extrapyramidal disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 208000001431 Psychomotor Agitation Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010038743 Restlessness Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000015706 neuroendocrine disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 201000004240 prostatic hypertrophy Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000012201 sexual and gender identity disease Diseases 0.000 abstract 1
- 208000015891 sexual disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9811879.7A GB9811879D0 (en) | 1998-06-03 | 1998-06-03 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0102233A2 true HUP0102233A2 (hu) | 2002-05-29 |
Family
ID=10833098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0102233A HUP0102233A2 (hu) | 1998-06-03 | 1999-05-26 | 5-HT-receptorokhoz affinitással rendelkező N-[(benzo-dioxanil)-metil]-N-[(4-piperidil)-metil]-amin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1087964A1 (pt) |
| JP (1) | JP2002517392A (pt) |
| KR (1) | KR20010052526A (pt) |
| CN (1) | CN1304408A (pt) |
| AR (1) | AR018622A1 (pt) |
| AU (1) | AU4369599A (pt) |
| BG (1) | BG104988A (pt) |
| BR (1) | BR9910927A (pt) |
| CA (1) | CA2333756A1 (pt) |
| CO (1) | CO5021190A1 (pt) |
| GB (1) | GB9811879D0 (pt) |
| HR (1) | HRP20010005A2 (pt) |
| HU (1) | HUP0102233A2 (pt) |
| ID (1) | ID27067A (pt) |
| IL (1) | IL139552A0 (pt) |
| NO (1) | NO20006041D0 (pt) |
| PL (1) | PL344594A1 (pt) |
| SK (1) | SK17602000A3 (pt) |
| TR (1) | TR200003569T2 (pt) |
| WO (1) | WO1999062902A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9915616D0 (en) * | 1999-07-05 | 1999-09-01 | Knoll Ag | Therapeutic agents |
| GB0007376D0 (en) * | 2000-03-28 | 2000-05-17 | Knoll Ag | Therapeutic agents |
| EP1284731A1 (en) * | 2000-05-12 | 2003-02-26 | Solvay Pharmaceuticals B.V. | Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders |
| NZ522116A (en) * | 2000-05-12 | 2004-04-30 | Solvay Pharmaceuticals B | Piperazine and piperidine compounds that have partial agonism towards dopamine D2-receptor subfamily and affinity for relevant serotonin and/or noradrenergic receptors |
| AU2006214233A1 (en) | 2005-02-17 | 2006-08-24 | Wyeth | Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2681325B1 (fr) * | 1991-09-16 | 1993-12-17 | Fabre Medicament Pierre | Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique. |
| FR2701479B1 (fr) * | 1993-02-11 | 1995-05-12 | Pf Medicament | Nouveaux dérivés hétérocycliques de l'aminométhyl-4 pipéridine, leur préparation et leur application en thérapeutique. |
| GB9318431D0 (en) * | 1993-09-06 | 1993-10-20 | Boots Co Plc | Therapeutic agents |
| GB9514380D0 (en) * | 1995-07-13 | 1995-09-13 | Knoll Ag | Therapeutic agents |
-
1998
- 1998-06-03 GB GBGB9811879.7A patent/GB9811879D0/en not_active Ceased
-
1999
- 1999-05-26 JP JP2000552113A patent/JP2002517392A/ja active Pending
- 1999-05-26 TR TR2000/03569T patent/TR200003569T2/xx unknown
- 1999-05-26 CA CA002333756A patent/CA2333756A1/en not_active Abandoned
- 1999-05-26 KR KR1020007013670A patent/KR20010052526A/ko not_active Application Discontinuation
- 1999-05-26 EP EP99926434A patent/EP1087964A1/en not_active Ceased
- 1999-05-26 PL PL99344594A patent/PL344594A1/xx not_active Application Discontinuation
- 1999-05-26 IL IL13955299A patent/IL139552A0/xx unknown
- 1999-05-26 HU HU0102233A patent/HUP0102233A2/hu unknown
- 1999-05-26 CN CN99806908A patent/CN1304408A/zh active Pending
- 1999-05-26 ID IDW20002519A patent/ID27067A/id unknown
- 1999-05-26 SK SK1760-2000A patent/SK17602000A3/sk unknown
- 1999-05-26 WO PCT/EP1999/003648 patent/WO1999062902A1/en not_active Application Discontinuation
- 1999-05-26 AU AU43695/99A patent/AU4369599A/en not_active Abandoned
- 1999-05-26 BR BR9910927-1A patent/BR9910927A/pt not_active IP Right Cessation
- 1999-06-03 CO CO99035020A patent/CO5021190A1/es unknown
- 1999-06-03 AR ARP990102619A patent/AR018622A1/es not_active Application Discontinuation
-
2000
- 2000-11-27 BG BG104988A patent/BG104988A/bg unknown
- 2000-11-29 NO NO20006041A patent/NO20006041D0/no not_active Application Discontinuation
-
2001
- 2001-01-02 HR HR20010005A patent/HRP20010005A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1087964A1 (en) | 2001-04-04 |
| HRP20010005A2 (en) | 2001-12-31 |
| WO1999062902A1 (en) | 1999-12-09 |
| TR200003569T2 (tr) | 2001-04-20 |
| GB9811879D0 (en) | 1998-07-29 |
| NO20006041L (no) | 2000-11-29 |
| JP2002517392A (ja) | 2002-06-18 |
| ID27067A (id) | 2001-02-22 |
| AR018622A1 (es) | 2001-11-28 |
| SK17602000A3 (sk) | 2001-08-06 |
| CN1304408A (zh) | 2001-07-18 |
| KR20010052526A (ko) | 2001-06-25 |
| PL344594A1 (en) | 2001-11-05 |
| BG104988A (bg) | 2001-11-30 |
| AU4369599A (en) | 1999-12-20 |
| IL139552A0 (en) | 2002-02-10 |
| NO20006041D0 (no) | 2000-11-29 |
| CA2333756A1 (en) | 1999-12-09 |
| CO5021190A1 (es) | 2001-03-27 |
| BR9910927A (pt) | 2001-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO960888L (no) | Bicykliske aromatiske forbindelser som terapeutiske midler | |
| AU1794097A (en) | Tropane-derivatives, their preparation and use | |
| TW413679B (en) | Lactam derivatives useful as psychotherapeutic agents and pharmaceutical compositions containing them | |
| CN1675215A (zh) | 作为烟碱性乙酰胆碱拮抗剂的芳基取代的二氮杂双环烷烃 | |
| AU626490B2 (en) | Neuroprotective 3-piperidino-4-hydroxychroman derivatives | |
| HUP0102233A2 (hu) | 5-HT-receptorokhoz affinitással rendelkező N-[(benzo-dioxanil)-metil]-N-[(4-piperidil)-metil]-amin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| JP2008506640A (ja) | 情動障害、疼痛、ａｄｈｄおよび腹圧性尿失禁の治療に使用するための２−（１ｈ−インドリルスルファニル）−アリールアミン誘導体 | |
| ZA965921B (en) | Therapeutic agents. | |
| WO2003016274A3 (en) | 2-substituted piperidines that are ligands for monoamine receptors and transporters | |
| WO2001072741A3 (en) | N-benzodioxanylmethyl-1-piperidyl-methylamine compounds for the treatment of central nervous system disorders | |
| Peglion et al. | Improvement in the Selectivity and Metabolic Stability of the Serotonin 5-HT1A Ligand, S 15535: A Series of cis-and trans-2-(Arylcycloalkylamine) 1-Indanols | |
| YU32700A (sh) | Postupak za dobijanje sertralina iz hiralnog tetralona | |
| BG102084A (en) | Condensed thiazole derivativs having affinity to 5-ht receptors | |
| Höök et al. | Synthesis of (+)‐(R)‐and (−)‐(S)‐5‐hydroxy‐2‐methyl‐2‐dipropylaminotetralin: Effects on rat hippocampal output of 5‐HT, 5‐HIAA, and DOPAC as determined by in vivo microdialysis |